After more than a decade of encapsulated cell technology (ECT) development, spanning preclinical research, manufacturing and clinical evaluation in oncology, Release Tx was established in 2023 to bring ECT to the CNS. Recognising the modality’s potential to overcome the longstanding challenge of reliably delivering large therapeutic molecules such as proteins to the brain, Release Tx set out to develop a scalable macroencapsulation approach that encapsulates engineered protein-secreting cells within a biocompatible, ultra-compact and retrievable implant for sustained local delivery beyond the blood-brain barrier.

 

That journey continues in close collaboration with the University of Geneva, Geneva University Hospitals and the Paris Brain Institute, bringing together world-leading academic and neurological expertise to advance clinical translation in the CNS.